Albany, New York, July 5, 2018: Growth of the rheumatoid arthritis market is attributed to macroeconomic aspects like increasing geriatric population, which is pushing the population affected by this disease. As per the report, the prevalence of this disease is recorded to be relatively higher in women. Research says that one in every 12 women develops rheumatoid arthritis during her lifetime. Lately, there has been an increase in awareness pertaining to rheumatoid arthritis treatment market, mostly in the developed regions. The global rheumatoid arthritis market attained a market value of over US$ 23,900 Mn in 2017 & is slated to grow at a CAGR of 5.9% from 2017 to 2025. These insights are obtained from a new report, titled “Global Rheumatoid Arthritis Treatment Market– Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025,” recently added to the holistic repository of Market Research Reports Search Engine (MRRSE).
This rising awareness of rheumatoid arthritis among people has exalted the rate of disease treatment, overshadowing the preference for symptoms treatment. With rising awareness, people are more aware of rheumatoid arthritis and subsequently are seeking different treatment methods on a large scale. This is a major factor which, in turn, is poised to magnify the sales of drugs in the rheumatoid arthritis market. Additionally, a bunch of new products are also expected to hit the rheumatoid arthritis market within the next eight years, which will glorify the future prospects of the global market.
Global Rheumatoid Arthritis Treatment Market: Conventional DMARD Therapies to Witness Highest Adoption
Conventional DMARDs has been the most standard treatment method for rheumatoid arthritis. The conventional DMARD drugs are available in different forms, such as oral & parenteral. Each dosage form has a different treatment regime associated with it. High adoption of conventional DMARD is foreseen to prevail in the global market. Biological DMARD is composed of agents which have been approved for the treatment of rheumatoid arthritis. The report doesn’t entail information about any biologic treatment which is under investigation or not approved by the regulatory authorities.
Several DMARDs are gaining momentum as first-line treatment for rheumatoid arthritis, such as sulphasalazine, methotrexate, and hydroxychloroquine. Key manufacturers in the market are scrutinizing several novel antirheumatic disease- modifying agents, which are anticipated to enter the market in the next 10 years. This, in turn, will elevate the uptake of drugs for rheumatoid arthritis fostering the global market growth.
What are the Key Questions Addressed in the Report?
Here are some of the prominent questions answered in the report which would be of great importance for the manufacturers in the market:
Browse Full Global Rheumatoid Arthritis Treatment Market Report with TOC : https://www.mrrse.com/rheumatoid-arthritis-treatment-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207